Alternative Data for Biohaven
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 88 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,716 | Sign up | Sign up | Sign up |
| Instagram Followers | 2,846 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 42 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,368 | Sign up | Sign up | Sign up |
| X Followers | 2,231 | Sign up | Sign up | Sign up |
| X Mentions | 20 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,010 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 74 | Sign up | Sign up | Sign up |
| Linkedin Employees | 395 | Sign up | Sign up | Sign up |
About Biohaven
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.
| Price | $13.14 |
| Target Price | Sign up |
| Volume | 4,110,000 |
| Market Cap | $1.58B |
| Year Range | $7.79 - $20.56 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Biohaven price target raised by $5 at BofA, here's whyJanuary 13 - Thefly.com |
 |
Biohaven reports 'positive' early experience from Priority Degrader ProgramsJanuary 12 - Thefly.com |
 |
Biohaven Ltd. (BHVN) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 11 - SeekingAlpha |
|
Biohaven MDD failure a 'net positive' for Xenon Pharmaceuticals, says StifelDecember 26 - Thefly.com |
|
William Blair views Biohaven depression miss as disappointingDecember 26 - Thefly.com |
|
Biohaven negative study 'disappointing but not that surprising,' says LeerinkDecember 26 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 1.1M | -1.1M | -173M | -172M | -1.640 |
| Q2 '25 | 0 | 0 | 0 | -198M | -210M | -1.940 |
| Q1 '25 | 0 | 1M | -1M | -222M | -219M | -2.170 |
| Q4 '24 | 3.8M | 1.9M | 1.9M | -187M | -187M | -1.710 |
| Q3 '24 | 0 | 1M | -1M | -160M | -176M | -1.740 |
Insider Transactions View All
| Clark George C. filed to buy 20,000 shares at $8.5. November 18 '25 |
| Coric Vlad filed to buy 740,546 shares at $7.5. November 17 '25 |
| Bailey Gregory filed to buy 2,020,071 shares at $7.5. November 17 '25 |
| CHILDS JOHN W filed to buy 5,653,904 shares at $7.5. November 17 '25 |
| CHILDS JOHN W filed to buy 25,291 shares at $30.7. March 5 '25 |
Similar companies
Read more about Biohaven (BHVN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Biohaven
The Market Cap of Biohaven is $1.58B.
Currently, the price of one share of Biohaven stock is $13.14.
The BHVN stock price chart above provides a comprehensive visual representation of Biohaven's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biohaven shares. Our platform offers an up-to-date BHVN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Biohaven (BHVN) does not offer dividends to its shareholders. Investors interested in Biohaven should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Biohaven are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
